We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Redx Pharma Plc | REDX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -2.70% | 9.00 | 12:19:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.00 | 8.75 | 9.00 | 9.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 18/4/2024 10:23 by blackhorse23 AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEN |
Posted at 10/4/2024 15:23 by blackhorse23 Money moving to APH [alliance pharma] , dividend announcement in 7 days |
Posted at 26/3/2024 18:44 by muchodinero If you read through the Jazz results it mentions the Redx Pharma deals under heading Business Updates/Corporate Development........."KRAS Inhibitor Program Agreement: In February 2024, the Company acquired Redx Pharma's KRAS inhibitor program, which includes G12D selective and pan-KRAS molecules, further expanding Jazz's early-stage oncology pipeline."....... |
Posted at 26/3/2024 15:39 by muchodinero Jazz Pharma post record sales for 2023 including over $1 billion 4th Qtr sales for first time. Great set of results for Jazz Pharma and includes mention of buying rights to Redx Kras inhibitor in the results. A great global Pharma partner for Redx it appears and potential $870 million in milestone and future royalty payments in the future. Also payments to Redx for future development work on KRAS programme as well it seems? GLA Adyor! |
Posted at 15/2/2024 07:21 by bermudashorts paulscbRedx have another $15m in potential near term milestones from the previous deals with Jazz and AstraZeneca. |
Posted at 23/2/2023 09:18 by pejaten umm. terms seem unfair to REDX |
Posted at 04/9/2022 14:59 by knitcraft Put RXC004 into your search Engine then refer to my last post.It gives real hope for specialist cancer and fibrosis treatment of previously extremly hard to treat tumours. .....and potentially will give you the opportunity to buy into RedX before the news is widely available as to just who is responsible for this potential life-saving research. |
Posted at 04/9/2022 14:37 by knitcraft The following news item was first published in The "I" last week and has been subsequently picked up by other publications and TV news. The link below is to an ITV news item.The intriguing and very important information that is missing from all the items, is the name of the company doing the research on RXC004. It happens to be RedX and when that fact becomes widely known I would expect a reassessment of the value of RedX. In June Trinity Delta,a reputable research company specialising in biomedicals, valued RedX shares on an undiluted basis at £1.38. The share price is currently 60p. Redx has at least 4 very promising research streams on the go. From the research note in June 2022 Redx Pharma continues to deliver, with H122 results highlighting broad progress across the pipeline. The lead assets, RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are advancing through Phase II and Phase I trials respectively, with further value inflection expected during 2022-23. Milestone receipts from AstraZeneca and Jazz Pharmaceuticals are tangible evidence of further progress with partnered programmes. Selection of RXC008, a GI targeted ROCK inhibitor as the next development candidate demonstrates earlier stage development is similarly bearing fruit. Our new rNPV-based valuation, updated to reflect H122 results and the May £34.3m (gross) equity raise, is £458m (vs £434m), or 138p/share. It is worth looking at the company in more detail to fully appreciate what they are about. Look at the highly qualified team that has been assembled. Also check the lines of research they are pursuing and the major pharmaceutical companies they are associated with. Also have look at the major shareholders involved. Now look at this. Very few know this is about RedX. I suspect they soon will! |
Posted at 23/12/2021 07:39 by wapper Another great Milestone payment RNS. Well done REDX and Merry Christmas all holders. |
Posted at 09/12/2021 08:29 by wapper UK, 9 December 2021 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that a milestone payment from Jazz Pharmaceuticals (NASDAQ: JAZZ) has been triggered as a result of entering the second year of the oncology research collaboration with the Company.The milestone payment of $10 million arises in accordance with the terms of the research collaboration agreement announced on 9 September 2020. Under the agreement to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway, Redx is responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. In addition to the $20 million in payments that have now been realised, Redx may receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each programme. The next milestone is payable upon successful IND submission and all subsequent milestones are contingent on successful completion of the relevant stages of development. In addition, Redx is eligible for tiered royalties in mid-single digit percentages, based on any future net sales. Lisa Anson, Chief Executive Officer of Redx, commented: "We are extremely pleased to extend our productive oncology research collaboration with Jazz into its second year. This is based on advancing our programmes in this key signalling pathway and reflects Redx's core strength in discovering highly targeted potential drug candidates. We look forward to further progress in partnership with Jazz." Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral Porcupine inhibitor, RXC004, targeting Wnt-ligand driven tumours, which has recently entered a Phase 2 trial in genetically selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and the oral selective ROCK2 inhibitor, RXC007, being developed for idiopathic pulmonary fibrosis, where first in human studies commenced in June 2021. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
